Covid-19

#Cancer #Cancer research #Carbon emissions #Covid-19 #Drug development #Drug discovery #Graft vs Host Disease #Monkeypox #Sustainability

Latest industry updates for the DDW Highlights series

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we learned the shocking statistic that… Read More

#News

#Cancer #Cancer research #Carbon emissions #Covid-19 #Drug development #Drug discovery #Graft vs Host Disease #Monkeypox #Sustainability

This week in drug discovery (7-11 November)

News round-up for 7-11 November by DDW Digital Content Editor Diana Spencer  This week we learned the shocking statistic that a third of scientific researchers have, or know a close colleague who has, experienced abuse after posting research online.  It wasn’t all bad news, however, as top… Read More

#News

#Covid-19 #Geographic atrophy #Immunology / Virology & Vaccines #Malaria #Neuroscience #Psychedelics

Catch up on the latest DDW Highlights episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a week that saw magic mushrooms making the… Read More

#News

#Covid-19 #Covid-19 vaccine #Drug development #Drug discovery #Gene therapy #Geographic atrophy #Malaria #Monoclonal antibodies #Psychedelics #Treatment-resistant depression

This week in drug discovery (31 October – 4 November)

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Meanwhile, the quest to understand… Read More

#News

Outbreak map of the world
#Covid-19 #Global.health #Infectious diseases #Monkeypox #Outbreak #Pandemic #Pandemic prevention #Pandemic response

Pandemic data platform will model emerging infectious diseases

The Rockefeller Foundation will provide $3 million in new funding for Global.health (G.h) – an open-source platform for scientific pandemic data.  The investment will allow the platform to expand its international partnerships and modernise the global effort around coordinated pandemic prevention, surveillance, and response. Co-developed by researchers and engineers… Read More

#Covid-19 #News

#Biochemistry #Covid-19 #Epstein-Barr virus

Listen now: New DDW Highlights podcast episode

The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Over the last seven days we’ve seen discoveries that could… Read More

#News

Dr Nevan Krogran receives Legion of Honour
#Awards #Covid-19 #Institut Pasteur #SARS-CoV-2 #UCSF

Covid-19 research group founder receives Legion of Honor 

Dr Nevan Krogan, Founder of the UC San Francisco (UCSF) Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG) and Director of QBI, has been awarded France’s Legion of Honor.  The award was given for forming an international research collaboration and for scientific contributions utilising a… Read More

#Covid-19 #News

Preparing Covid-19 vaccine for injection
#Covid booster #Covid-19 #Covid-19 vaccine #MHRA #Phase III trial #Vaxxinity

New class of Covid-19 booster completes enrollment of Phase III trial

Global Phase III topline data is expected later this year for a new class of Covid-19 booster vaccine. Vaxxinity has completed enrollment for the trial, co-sponsored by the Coalition for Epidemic Preparedness Innovations (CEPI). Its UB-612 will be evaluated as a heterologous booster vaccine to mRNA, adeno-vectored, and inactivated primary… Read More

#Covid-19 #Editor's Choice #News

Covid-19 vaccination
#Covid-19 #Covid-19 vaccine #Immunocompromised #Immunology / Virology & Vaccines

Covid-19 vaccine less effective in the immunocompromised 

A new study in the US has revealed that the Covid-19 vaccine is less effective in people with weakened immune systems.  The research from the Centers for Disease Control and Prevention’s VISION Network analysed real-world data on mRNA vaccine effectiveness during Omicron BA.4 and BA.5 predominance… Read More

#Covid-19 #News #Trending News

#Biomarkers #Cancer research #Click chemistry #Covid-19 #Drug development #Drug discovery #Epstein-Barr virus #Monoclonal antibodies #mRNA #Oncology #Our Future Health #Pancreatic cancer

This week in drug discovery (24-28 October)

News round-up for 24-28 October by DDW Digital Content Editor Diana Spencer  Over the last seven days we’ve seen discoveries that could lead to new treatments for Covid-19, pancreatic cancer and Epstein-Barr virus, as well as the launch of the UK’s largest health research programme and the innovative application of… Read More

#News

Lipid nanoparticle mRNA vaccine entering a human cell
#Covid-19 #Covid-19 treatment #hACE2 #mRNA #SARS-CoV-2

Could mRNA become a ‘universal’ Covid-19 treatment? 

New research suggests messenger RNA can be effectively used as a ‘universal’ therapy against different coronaviruses.  A scientist at Oregon State University has demonstrated in a mouse model that it’s possible to prompt the production of a protein that can block multiple variants of the SARS-CoV-2… Read More

#Covid-19 #News

#Antibiotic resistance #Antibiotics #Contraception #Contraceptive pill #Covid-19 #Drug development #Drug discovery #Idiopathic pulmonary fibrosis #Respiratory syncytial virus

This week in drug discovery (17-21 October)

News round-up for 17-21 October by DDW Digital Content Editor Diana Spencer  Amid continued concern about antibiotic resistance, the headline news this week was the discovery of a new antibiotic that could be effective against some of the most treatment-resistant pathogens.   However, there was also… Read More

#News

Covid-19
#Boston University #Covid-19 #National Institutes of Health (NIH) #NIAID

Boston researchers criticised over creation of Covid-19 variant

A research team from Boston University has caused controversy for work involving the creation of a hybrid SARS-CoV-2 virus.  Researchers from Boston University’s National Emerging Infectious Diseases Laboratories conducted a study1 to create a chimeric virus which combined the spike protein of the Omicron variant with the… Read More

#Covid-19 #News

Automated pipetting
#App note #Automated liquid handling #Automation / robotics #Clinical diagnostics #Covid-19 #Liquid handling #SARS-CoV-2

New App Note on automated Sars-CoV-2 clinical diagnostics

A new App Note is now available, sponsored by Analytik Jena: Rapid Development of Automated Sars-CoV-2 Clinical Diagnostics. Download to learn about: How to create and share an automated workflow for rapid development and validation of SARS-CoV-2 clinical diagnostics. The highly scalable liquid handling platform, CyBio FeliX for clinical… Read More

#News

App Note: Rapid Development of Automated Sars-CoV-2 Clinical Diagnostics
#App note #Automated liquid handling #Automation / robotics #Clinical diagnostics #Covid-19 #Liquid handling #SARS-CoV-2

Rapid development of automated Sars-CoV-2 clinical diagnostics

Download the App Note to learn about: How to create and share an automated workflow for rapid development and validation of SARS-CoV-2 clinical diagnostics. The highly scalable liquid handling platform, CyBio FeliX for clinical diagnostics – it provides magnetic bead-based nucleic acid extraction, eliminating laborious and time-consuming column-based binding and… Read More

#App Notes #Intelligence #Resources

mRNA vaccines
#Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #mRNA #Vaccines

Preparing for new-era drug modalities with technology 

Listen to this article on the DDW podcast: Samsung Biologics’ Senior Vice President, James Park, explores the opportunities emerging for CDMOs to support mRNA developers as they explore new therapeutic areas for patients.  Prior to the pandemic, messenger RNA (mRNA) drug development was niche and predominantly pointed at different disease targets,… Read More

#Exclusive Content